( Log in to your Wikimedia account to use OAuth instead of Quickstatements for updates.)
Author name:
Limit:
Additional SPARQL filters separated by semicolons (eg. for papers on Zika virus, enter wdt:P921 wd:Q202864):
Filter potential authors as well?

Potential publications

13 publications found

Click here to create clusters based on exact author strings rather than rougher matches.

Group #1

TitleAuthors (identified)Published InIdentifier(s)TopicPublished DateMatch?
c-Jun N-terminal kinases mediate reactivation of Akt and cardiomyocyte survival after hypoxic injury in vitro and in vivo.[1]Zhili Shao, [2]Kausik Bhattacharya, [3]Eileen Hsich, [4]Larry Park, [5]Brian Walters, [6]Ursula Germann, [7]Yow-Ming Wang, [8]John Kyriakis, [9]Ramon Mohanlal, [10]Keisuke Kuida, [11]Mark Namchuk, [12]Francesco Salituro, [13]Yung-mae Yao, [14]Wei-min Hou, [15]Xin Chen, [16]Mark Aronovitz, [17]Philip N Tsichlis, [18]Susmita Bhattacharya, [19]Thomas Force, [20]Heiko Kilter [Full author list]Circulation Research [missing]DOI: 10.1161/01.RES.0000197781.20524.B9 [ORCID]
PubMed: 16306447 [ORCID]
hypoxia [missing]2005-11-23
Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease[1]Thomas Force, [2]Keisuke Kuida, [3]Mark Namchuk, [4]Keykavous Parang, [5]John M Kyriakis [Full author list]Circulation [missing]DOI: 10.1161/01.CIR.0000118538.21306.A9 [ORCID]
PubMed: 15023894 [ORCID]
cardiovascular disease [missing]2004-03-01

Group #2

TitleAuthors (identified)Published InIdentifier(s)TopicPublished DateMatch?
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).[1]Ursula A Germann, [2]Brinley F Furey, [3]William Markland, [4]Russell R Hoover, [5]Alex M Aronov, [6]Jeffrey J Roix, [7]Michael Hale, [8]Diane M Boucher, [9]David A Sorrell, [10]Gabriel Martinez-Botella, ..., [16]Anna Groover, [17]Gary DeCrescenzo, [18]Mark Namchuk, [19]Caroline M Emery, [20]Saurabh Saha, ... [Full author list]Molecular Cancer Therapeutics [missing]DOI: 10.1158/1535-7163.MCT-17-0456 [ORCID]
PubMed: 28939558 [ORCID]
2017-09-22
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases[1]Luc J Farmer, [2]Mark W Ledeboer, [3]Thomas Hoock, [4]Michael J Arnost, [5]Randy S Bethiel, [6]Youssef L Bennani, [7]James J Black, [8]Christopher L Brummel, [9]Ananthsrinivas Chakilam, [10]Warren A Dorsch, ..., [24]Pamela McCarthy, [25]David Messersmith, [26]Mark Namchuk, [27]Luke Oh, [28]Marina S Penney, ... [Full author list]Journal of Medicinal Chemistry [missing]DOI: 10.1021/ACS.JMEDCHEM.5B00301 [ORCID]
PubMed: 26230873 [ORCID]
2015-09-24
VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia.[1]David K Heidary, [2]George Huang, [3]Diane Boucher, [4]Jianguo Ma, [5]Cornelia Forster, [6]Ron Grey, [7]Jinwang Xu, [8]Michael Arnost, [9]Deborah Choquette, [10]Guanjing Chen, [11]Jie-Hua Zhou, [12]Yung-Mae Yao, [13]Edward D Ball, [14]Mark Namchuk, [15]Robert J Davies, [16]Greg Henkel [Full author list]Journal of Medicinal Chemistry [missing]DOI: 10.1021/JM201198W [ORCID]
PubMed: 22221201 [ORCID]
leukemia [missing]2012-01-05
Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia[1]Robert J Davies, [2]Albert C Pierce, [3]Cornelia Forster, [4]Ron Grey, [5]Jinwang Xu, [6]Michael Arnost, [7]Deborah Choquette, [8]Vincent Galullo, [9]Shi-Kai Tian, [10]Greg Henkel, [11]Guanjing Chen, [12]David K Heidary, [13]Joanne Ma, [14]Cameron Stuver-Moody, [15]Mark Namchuk [Full author list]Journal of Medicinal Chemistry [missing]DOI: 10.1021/JM200712H [ORCID]
PubMed: 21970471 [ORCID]
2011-10-04
Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole[1]Tiansheng Wang, [2]John P Duffy, [3]Jian Wang, [4]Summer Halas, [5]Francesco G Salituro, [6]Albert C Pierce, [7]Harmon J Zuccola, [8]James R Black, [9]James K Hogan, [10]Scott Jepson, ..., [19]Ursula A Germann, [20]Bin Fan, [21]Mark Namchuk, [22]Youssef L Bennani, [23]Mark W Ledeboer [Full author list]Journal of Medicinal Chemistry [missing]DOI: 10.1021/JM901383U [ORCID]
PubMed: 20014869 [ORCID]
2009-12-24
In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats[1]François Maltais, [2]Young Chun Jung, [3]Minzhang Chen, [4]Jerry Tanoury, [5]Robert B Perni, [6]Nagraj Mani, [7]Leena Laitinen, [8]Hui Huang, [9]Shengkai Liao, [10]Hongying Gao, ..., [18]S Pazhanisamy, [19]Scott Raybuck, [20]Mark Namchuk, [21]Youssef L Bennani [Full author list]Journal of Medicinal Chemistry [missing]DOI: 10.1021/JM901023F [ORCID]
PubMed: 19894743 [ORCID]
2009-12-01

Misc

TitleAuthors (identified)Published InIdentifier(s)TopicPublished DateMatch?
An open toolkit for tracking open science partnership implementation and impact.[1]E Richard Gold, [2]Sarah E Ali-Khan, [3]Liz Allen, [4]Lluís Ballell, [5]Manoel Barral Netto, [6]David Carr, [7]Damien Chalaud, [8]Simon Chaplin, [9]Matthew S Clancy, [10]Patricia Clarke, ..., [30]Daniel Mietchen, [31]Jennifer C Molloy, [32]Mark Namchuk, [33]Brian Nosek, [34]Sébastien Paquet, ... [Full author list]Gates Open Research [missing]DOI: 10.12688/GATESOPENRES.12958.2 [ORCID]
PubMed: 31850398 [ORCID]
open science [missing]2019-12-04Mark Namchuk (Q64764494; 3 items)
Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates[1]Jacobi I Cunningham, [2]David J Eyerman, [3]Mark S Todtenkopf, [4]Reginald L Dean, [5]Daniel R Deaver, [6]Connie Sanchez, [7]Mark Namchuk [Full author list]Journal of Psychopharmacology [missing]DOI: 10.1177/0269881119856850 [ORCID]
PubMed: 31294646 [ORCID]
2019-07-11
Delivery of long-acting injectable antivirals: best approaches and recent advances[1]Magali B Hickey, [2]Elaine Merisko-Liversidge, [3]Julius F Remenar, [4]Mark Namchuk [Full author list]Current Opinion in Infectious Diseases [missing]DOI: 10.1097/QCO.0000000000000214 [ORCID]
PubMed: 26524333 [ORCID]
2015-12-01
(S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18[1]Woods Wannamaker, [2]Robert Davies, [3]Mark Namchuk, [4]John Pollard, [5]Pamella Ford, [6]George Ku, [7]Caroline Decker, [8]Paul Charifson, [9]Peter Weber, [10]Ursula A Germann, [11]Keisuke Kuida, [12]John C R Randle [Full author list]Journal of Pharmacology and Experimental Therapeutics [missing]DOI: 10.1124/JPET.106.111344 [ORCID]
PubMed: 17289835 [ORCID]
2007-02-08
Designing screens: how to make your hits a hit.[1]W Patrick Walters, [2]Mark Namchuk [Full author list]Nature Reviews Drug Discovery [missing]DOI: 10.1038/NRD1063 [ORCID]
PubMed: 12669025 [ORCID]
2003-04-01

Potential author items

NameDescriptionAuthored itemsIdentifiersEmployer(s)
Mark Namchukresearcher3ORCID: 0000-0002-5220-2275
Alkermes (United States) [missing]
Harvard Medical School [missing]
University of British Columbia [missing]
Other Q number of this author

New Author Item

(if the author you are looking for is not listed above and otherwise not yet in Wikidata)
Author name:
Check ORCID for Mark Namchuk | Author has ORCID ID:
Check VIAF for Mark Namchuk | Author has VIAF ID:
Check ResearchGate for Mark Namchuk | Author has ResearchGate Profile ID:
After creating the new author item, enter the Wikidata ID in the "Other Q number of this author" field above to link to their works.

Author items in these papers

Common author name strings in these papers

Publishing venues for these papers

Topics for these papers

Feedback
Source and documentation (at github)
Wikidata page